Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cemiplimab - Regeneron Pharmaceuticals

Next Previous
X
Search
Drug Profile

Cemiplimab - Regeneron Pharmaceuticals

Alternative Names: Cemiplimab-rwlc; Libtayo; REGN-2810; SAR-439684

Latest Information Update: 12 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer BioNTech; Columbia University; Dana-Farber Cancer Institute; Inovio Pharmaceuticals; ISA Pharmaceuticals; Regeneron Pharmaceuticals; Replimune; Sanofi; SillaJen Biotherapeutics; Sun Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center; University of Zurich
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer; Non-small cell lung cancer; Squamous cell cancer
  • Registered Cervical cancer
  • Phase III Malignant melanoma
  • Phase II Glioblastoma; Haemangiosarcoma; Head and neck cancer; Liver cancer; Oropharyngeal cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Multiple myeloma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • No development reported B-cell lymphoma; Cancer; Haematological malignancies; Renal cell carcinoma

Most Recent Events

  • 31 Oct 2024 Preregistration for Non-small cell lung cancer (Late-stage disease, First-line therapy, Combination therapy) in Japan (IV)
  • 31 Oct 2024 Preregistration for Non-small cell lung cancer (Late-stage disease, First-line therapy, Monotherapy) in Japan (IV)
  • 23 Oct 2024 Efficacy and pharmacodynamics data from a phase-I clinical trials in renal cell carcinoma presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top